<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>Insight数据库 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-23T20:32:50+08:00</updated>
  <subtitle>丁香园 Insight 数据库（db.dxy.cn），拥有申报、临床、上市、药企等 10 大核心数据。致力于分享医药行业政策解读、药企大事和药品申报情报等</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>丁苯酞大卖！石药三季营收 192.15 亿元，研发投入 22.66 亿元，抗肿瘤药物全线大增</title>
    <updated>2020-11-23T18:13:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/nvtI4qEEC7ZSMs-1eJBKDw</id>
    <link href="https://mp.weixin.qq.com/s/nvtI4qEEC7ZSMs-1eJBKDw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>明天见！苏州生物药研发策略沙龙拍了拍你</title>
    <updated>2020-11-23T18:13:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/YziIWqWNmCXBvh1Raq-M8g</id>
    <link href="https://mp.weixin.qq.com/s/YziIWqWNmCXBvh1Raq-M8g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>南京圣和药业的 1 类新药「和乐布韦片」拟纳入优先审评</title>
    <updated>2020-11-23T18:13:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/wUTdckM-CWPkBQa_g4v5qA</id>
    <link href="https://mp.weixin.qq.com/s/wUTdckM-CWPkBQa_g4v5qA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>今日 8 个仿制药通过一致性评价，3 个首家！</title>
    <updated>2020-11-23T18:13:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/SP5OkJjEdFmK_cQWI1J-mw</id>
    <link href="https://mp.weixin.qq.com/s/SP5OkJjEdFmK_cQWI1J-mw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>O+Y 联合疗法拟纳入优先审评，国内恶性胸膜间皮癌一线治疗新突破！</title>
    <updated>2020-11-23T18:13:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/JKsNN7dl1SevpYVRv_bKOQ</id>
    <link href="https://mp.weixin.qq.com/s/JKsNN7dl1SevpYVRv_bKOQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>默沙东四价 HPV 疫苗在华获批新适应症，年龄拓展至 9-19 岁</title>
    <updated>2020-11-23T18:13:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/d_LNqE-JrmpGjkdhFmJc1A</id>
    <link href="https://mp.weixin.qq.com/s/d_LNqE-JrmpGjkdhFmJc1A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>集采未中选「价高药」，个人自付比例提高 10% 或 20%</title>
    <updated>2020-11-23T18:13:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/msQKdgPj0Y7P92C8gBxGHg</id>
    <link href="https://mp.weixin.qq.com/s/msQKdgPj0Y7P92C8gBxGHg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Insight 策划 | 生物药研发策略沙龙，下周二苏州见！</title>
    <updated>2020-11-20T19:22:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/6m9O3-de5FVVYZ3M8scIpg</id>
    <link href="https://mp.weixin.qq.com/s/6m9O3-de5FVVYZ3M8scIpg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>一致性评价，这 23 家药企开始了（附名单）</title>
    <updated>2020-11-20T18:04:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/dPi7bvSlx2mkbMpSQyx2Zg</id>
    <link href="https://mp.weixin.qq.com/s/dPi7bvSlx2mkbMpSQyx2Zg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>拥有 2 款同类首款新药，德琪医药今日正式在港交所上市</title>
    <updated>2020-11-20T18:04:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/J1QiGbhImJx9Mju4ZqOLXg</id>
    <link href="https://mp.weixin.qq.com/s/J1QiGbhImJx9Mju4ZqOLXg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州「地舒单抗」新适应症获批！国内首款骨转移及骨相关事件 RANKL 抑制剂</title>
    <updated>2020-11-20T18:04:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/GHSmZ6EUTyvzeNhAvo1SZw</id>
    <link href="https://mp.weixin.qq.com/s/GHSmZ6EUTyvzeNhAvo1SZw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>通化东宝「超速效赖脯胰岛素注射液」获批临床</title>
    <updated>2020-11-20T18:04:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/V2XLv0LF6aRP1YpMgUmRRQ</id>
    <link href="https://mp.weixin.qq.com/s/V2XLv0LF6aRP1YpMgUmRRQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>再鼎 Repotrectinib 获批临床，ALK/ROS1/NTRK 重排晚期实体瘤</title>
    <updated>2020-11-20T18:04:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/m1fwBMDKUd5osEc2ZXOCEQ</id>
    <link href="https://mp.weixin.qq.com/s/m1fwBMDKUd5osEc2ZXOCEQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>您有一张免费参会券待领取 | 40+行业领袖齐聚，12月千人生物工艺盛会等你来撩！</title>
    <updated>2020-11-20T18:04:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/mi0LXY_06QPtMBgjAA-vJw</id>
    <link href="https://mp.weixin.qq.com/s/mi0LXY_06QPtMBgjAA-vJw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>刚刚！贝达药业「恩莎替尼」获批上市，首个国产 ALK 抑制剂</title>
    <updated>2020-11-19T10:13:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-19:/s/0hgU1C642cvchNKkFC0LLQ</id>
    <link href="https://mp.weixin.qq.com/s/0hgU1C642cvchNKkFC0LLQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>今日，9 款仿制药过评，6 个为首家，3 个注射剂</title>
    <updated>2020-11-19T10:13:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-19:/s/i6eBBi2_qFEmiR8UTWL-iA</id>
    <link href="https://mp.weixin.qq.com/s/i6eBBi2_qFEmiR8UTWL-iA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>扬子江药业「恩替卡韦口服溶液」首仿获批</title>
    <updated>2020-11-19T10:13:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-19:/s/UJhhSusEjvhkZTWh_MLztg</id>
    <link href="https://mp.weixin.qq.com/s/UJhhSusEjvhkZTWh_MLztg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞近一个月已有 12 款新药获批临床，「医药一哥」威力不减</title>
    <updated>2020-11-18T18:30:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/Ps_xUXKHUoRh8W3YOp8YxA</id>
    <link href="https://mp.weixin.qq.com/s/Ps_xUXKHUoRh8W3YOp8YxA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>针对 NSCLC，百济神州 PD-1 全球关键性 III 期临床达主要终点</title>
    <updated>2020-11-18T18:30:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/KB4AjM78E_cm0I9You8fsw</id>
    <link href="https://mp.weixin.qq.com/s/KB4AjM78E_cm0I9You8fsw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>荣昌生物 c-Met 靶向 ADC 国内首次获批临床</title>
    <updated>2020-11-18T18:30:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/_30CvOQ01SC2dJ2Fe6zi6A</id>
    <link href="https://mp.weixin.qq.com/s/_30CvOQ01SC2dJ2Fe6zi6A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>